Stem Cells International / 2015 / Article / Tab 4

Clinical Study

Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study

Table 4

Logistic regression analysis for the association between the occurrence of adverse event during allogeneic UCBSCs treatment and several predicting factors.

Predicting factorsSignificanceOdds ratio95% confidence interval
Lower boundUpper bound

Sex
 Female0.1244.4200.66429.417
 Male
Birth method
 Cesarean0.3810.5000.1062.362
 Natural birth
Birth weight
 Low birth weight0.5030.5230.0783.484
 Normal birth weight
Gestational age
 Preterm0.1454.4940.59533.961
 Full term
Neonatal jaundice
 Yes0.7961.2870.1918.669
 No
NHIE
 Yes0.5990.6810.1632.847
 No
Epilepsy
 Yes0.6271.4560.3206.623
 No
MIDP
 Yes0.6051.5140.3147.289
 No
Age at treatment initiation
 ≤10 years old0.03612.5431.178133.549
 >10 years old

Note. UCBSCs: umbilical cord blood stem cells; NHIE: neonatal hypoxic ischemic encephalopathy; MIDP: mother infected during pregnancy.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.